Riboflavin for pediatric migraine prophylaxis: what the trials actually show

← Back to articles

Riboflavin (vitamin B2) is one of the most widely recommended "natural" options for preventing migraine in children, largely on the strength of a single positive adult trial. But the question the title asks — what do the trials actually show in children? — has a more sobering answer. The two placebo-controlled pediatric trials that tested it both came back negative for their primary outcome. The case for riboflavin in childhood migraine rests less on demonstrated efficacy than on extrapolation from adults plus an exceptionally benign safety profile.

Why riboflavin was expected to help

Migraine has long been linked to impaired mitochondrial energy metabolism in the brain. Riboflavin is the precursor for flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), the cofactors that drive complexes I and II of the mitochondrial electron transport chain. The hypothesis, advanced in the 1990s, was that supraphysiologic doses (far above the 1–2 mg/day dietary requirement) might raise mitochondrial ATP-production capacity and so reduce attack frequency [1]. It is a coherent mechanistic story — but mechanism is not evidence, and dermatology, psychiatry, and headache medicine are full of biologically plausible therapies that failed in controlled trials.

The adult trial that started it all

The pivotal study is Schoenen and colleagues' 1998 randomized trial in 55 adults, who received riboflavin 400 mg/day or placebo for three months [2]. Using intention-to-treat analysis, riboflavin outperformed placebo in reducing attack frequency, and the proportion of "responders" (those improving by at least 50%) was 59% with riboflavin versus 15% with placebo, giving a number-needed-to-treat of about 2.3. The result was striking, the tolerability excellent, and the cost trivial — which is precisely why it has been so heavily extrapolated. It is, however, a single small single-center adult trial, and adults are not children.

What the pediatric trials show

Two randomized, double-blind, placebo-controlled trials have tested riboflavin specifically in children, and both are worth reading closely. MacLennan and colleagues (2008) randomized 48 children to riboflavin 200 mg/day or placebo. A 50%-or-greater reduction in headaches occurred in 14 of 21 children on placebo versus 12 of 27 on riboflavin — numerically favoring placebo, and not statistically significant (P = 0.125). There were no differences on any primary or secondary measure [3]. Bruijn and colleagues (2010) used a crossover design in 42 children at a lower dose of 50 mg/day; again there was no significant effect on migraine attack frequency (P = 0.44), although a secondary signal suggested possible benefit for milder, tension-type interval headaches [4]. In short, neither pediatric trial demonstrated that riboflavin prevents migraine attacks in children.

The high-placebo-response problem

The MacLennan trial highlights a problem that haunts all pediatric headache research: placebo response rates of 50% or higher are common in children, far exceeding what is typically seen in adults [3]. When two-thirds of placebo-treated children improve, the statistical room left for an active drug to prove itself is small, and trials of this size are underpowered to detect a modest true effect. So the negative pediatric results do not necessarily prove riboflavin is inert in children — they show that, at the doses and durations tested, no benefit over placebo could be demonstrated. That is an important distinction, but it is not the same as a positive finding.

How the evidence is summarized

A 2024 network meta-analysis of 45 randomized trials of pediatric migraine prophylaxis (3,771 children) placed riboflavin among agents associated with reduced attack frequency (ratio of means 0.50), but explicitly cautioned that this estimate was drawn from individual studies rather than replicated data, and concluded that more trials were required before any firm recommendation [5]. Narrative reviews of nutraceuticals in pediatric migraine reach the same verdict: the evidence base for riboflavin, magnesium, CoQ10, and similar agents is small and low in quality, and no definite conclusions about efficacy can be drawn [6][7]. This is why pediatric guidance describes riboflavin as a reasonable option rather than a recommended therapy.

Dosing, in practice

Pediatric headache clinics that do use riboflavin typically prescribe 100–400 mg/day, often split into two doses, with a 2–3 month trial before judging response. The doses tested in the negative pediatric trials (50 and 200 mg/day) were lower than the 400 mg/day adult dose, and some clinicians argue higher pediatric doses deserve a proper trial — but as of now that trial has not been done, so higher-dose pediatric efficacy remains unproven rather than established. Any decision to try riboflavin should be made with the child's clinician, alongside the evidence-supported options (topiramate, propranolol, amitriptyline) and non-drug measures such as sleep regularity, hydration, and headache-trigger management.

Safety and tolerability

Riboflavin's main appeal is its safety. It is water-soluble, and across the pediatric trials adverse events were minimal and comparable to placebo [3][4]. The most reliable effect is bright fluorescent-yellow urine — harmless, dose-dependent, and useful as an adherence marker. Mild gastrointestinal symptoms (loose stools, cramping) occur occasionally. No serious adverse events were reported in the controlled pediatric studies. Long-term safety of high-dose riboflavin beyond the trial durations has not been formally characterized, but no signal of harm has emerged. This favorable risk profile — not proven efficacy — is the honest basis for considering it.

Sources

1. Schoenen J, Lenaerts M, Bastings E. "High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study." Cephalalgia, 1994;14(5):328-9. PMID 7828189.
2. Schoenen J, Jacquy J, Lenaerts M. "Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial." Neurology, 1998;50(2):466-70. PMID 9484373.
3. MacLennan SC, Wade FM, Forrest KML, et al. "High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial." J Child Neurol, 2008;23(11):1300-4. PMID 18984840.
4. Bruijn J, Duivenvoorden H, Passchier J, et al. "Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial." Cephalalgia, 2010;30(12):1426-34. PMID 20974610.
5. Kohandel Gargari O, Aghajanian S, Togha M, et al. "Preventive Medications in Pediatric Migraine: A Network Meta-Analysis." JAMA Netw Open, 2024;7(10):e2438666. PMID 39388181.
6. Orr SL. "The Evidence for the Role of Nutraceuticals in the Management of Pediatric Migraine: a Review." Curr Pain Headache Rep, 2018;22(5):37. PMID 29619575.
7. Sangermani R, Boncimino A. "The use of nutraceutics in children's and adolescent's headache." Neurol Sci, 2017;38(Suppl 1):121-124. PMID 28527085.